Oventus Medical (ASX:OVN) Presentation, FNN Investor Event, October 2018, Sydney

Company Presentations

Oventus Medical Limited (ASX:OVN) founder, Managing Director and CEO, Dr Chris Hart discusses the company's sales push into the US, new product development and changes in the treatment of sleep apnoea at FNN's Investor Event. 

Key points:


- Oventus is commercialising its O2Vent™ to treat Obstructive Sleep Apnoea
- Breathing is briefly interrupted or becomes very shallow during sleep
- 80 per cent of sleep apnoea sufferers are currently out of care
- Conventional treatment can be intolerable
- 100 per cent patients treated without using a full face mask
- Distribution agreement with Modern Dental Group

For more, watch founder, Managing Director and CEO, Dr Chris Hart present. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.